Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 469

1.

Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan Africa.

Boyd A, Kouamé MG, Houghtaling L, Moh R, Gabillard D, Maylin S, Abdou Chekaraou M, Delaugerre C, Anglaret X, Eholié SP, Danel C, Zoulim F, Lacombe K; ANRS 12136 Temprano and ANRS 12240 VarBVA studies.

Trans R Soc Trop Med Hyg. 2019 Aug 1;113(8):437-445. doi: 10.1093/trstmh/trz021.

PMID:
31574151
2.

Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B.

Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, Rigopoulou E, Gatselis NK, Lyberopoulou A, Vlachogiannakos I, Manolakopoulos S, Dalekos GN, Zoulim F, Papatheodoridis GV.

J Viral Hepat. 2019 Sep 28. doi: 10.1111/jvh.13211. [Epub ahead of print]

PMID:
31562748
3.

Therapeutic strategies for hepatitis B virus infection: towards a cure.

Fanning GC, Zoulim F, Hou J, Bertoletti A.

Nat Rev Drug Discov. 2019 Aug 27. doi: 10.1038/s41573-019-0037-0. [Epub ahead of print] Review.

PMID:
31455905
4.

LARP1 binding to hepatitis C virus particles is correlated with intracellular retention of viral infectivity.

Plissonnier ML, Cottarel J, Piver E, Kullolli M, Centonze FG, Pitteri S, Farhan H, Meunier JC, Zoulim F, Parent R.

Virus Res. 2019 Oct 2;271:197679. doi: 10.1016/j.virusres.2019.197679. Epub 2019 Aug 6.

PMID:
31398365
5.

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.

Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, Thimme R, Lugardon K, Martin P, Bastien B, Sansas B, Adda N, Halluard C, Bendjama K, Brandely M, Inchauspé G.

Hum Vaccin Immunother. 2019 Oct 4:1-12. doi: 10.1080/21645515.2019.1651141. [Epub ahead of print]

PMID:
31373537
6.

Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection.

Faure-Dupuy S, Delphin M, Aillot L, Dimier L, Lebossé F, Fresquet J, Parent R, Matter MS, Rivoire M, Bendriss-Vermare N, Salvetti A, Heide D, Flores L, Klumpp K, Lam A, Zoulim F, Heikenwälder M, Durantel D, Lucifora J.

J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30422-2. doi: 10.1016/j.jhep.2019.06.032. [Epub ahead of print]

PMID:
31349000
7.

BAY 41-4109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy.

Rat V, Seigneuret F, Burlaud-Gaillard J, Lemoine R, Hourioux C, Zoulim F, Testoni B, Meunier JC, Tauber C, Roingeard P, de Rocquigny H.

Antiviral Res. 2019 Sep;169:104557. doi: 10.1016/j.antiviral.2019.104557. Epub 2019 Jul 11.

PMID:
31302151
8.

Non-invasive biomarkers for chronic hepatitis B virus infection management.

Charre C, Levrero M, Zoulim F, Scholtès C.

Antiviral Res. 2019 Sep;169:104553. doi: 10.1016/j.antiviral.2019.104553. Epub 2019 Jul 6. Review.

PMID:
31288041
9.

[Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study].

Cohen D, Shimakawa Y, Ndow G, Sow A, Tamba S, Njie R, Lo G, Ghosh S, Toure-Kane C, Ka M, Mboup S, Okeke E, Toure S, Diop M, D'Alessandro U, Taylor-Robinson S, Mendy M, Zoulim F, Thursz MR, Lemoine M, Chemin I.

Med Sci (Paris). 2019 May;35(5):431-439. doi: 10.1051/medsci/2019076. Epub 2019 May 22. French.

10.

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.

Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH.

J Hepatol. 2019 Sep;71(3):473-485. doi: 10.1016/j.jhep.2019.04.017. Epub 2019 May 13.

PMID:
31096005
11.

Update of the statements on biology and clinical impact of occult hepatitis B virus infection.

Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS; Taormina Workshop on Occult HBV Infection Faculty Members.

J Hepatol. 2019 Aug;71(2):397-408. doi: 10.1016/j.jhep.2019.03.034. Epub 2019 Apr 18. Review.

12.

A global scientific strategy to cure hepatitis B.

Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e7.

13.

The Potential Implication of the Autonomic Nervous System in Hepatocellular Carcinoma.

Parent R, Gidron Y, Lebossé F, Decaens T, Zoulim F.

Cell Mol Gastroenterol Hepatol. 2019;8(1):145-148. doi: 10.1016/j.jcmgh.2019.03.002. Epub 2019 Apr 11. No abstract available.

14.

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.

Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S; ANRS/AFEF HEPATHER study group.

BMC Infect Dis. 2019 Apr 2;19(1):300. doi: 10.1186/s12879-019-3923-5.

15.

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.

Revill PA, Penicaud C, Brechot C, Zoulim F.

Genes (Basel). 2019 Apr 1;10(4). pii: E260. doi: 10.3390/genes10040260. Review.

16.

Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.

Liu Y, Zhou Y, Li X, Niu M, Chen R, Shao J, Si L, Luo D, Lin Y, Li L, Zhang K, Xiao X, Xu Z, Liu M, Lu M, Zoulim F, Xu D.

Emerg Microbes Infect. 2019;8(1):354-365. doi: 10.1080/22221751.2019.1584018.

17.

Biological basis for functional cure of chronic hepatitis B.

Martinez MG, Testoni B, Zoulim F.

J Viral Hepat. 2019 Jul;26(7):786-794. doi: 10.1111/jvh.13090. Epub 2019 Mar 29. Review.

PMID:
30803126
18.

Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.

Park ES, Lee AR, Kim DH, Lee JH, Yoo JJ, Ahn SH, Sim H, Park S, Kang HS, Won J, Ha YN, Shin GC, Kwon SY, Park YK, Choi BS, Lee YB, Jeong N, An Y, Ju YS, Yu SJ, Chae HB, Yu KS, Kim YJ, Yoon JH, Zoulim F, Kim KH.

J Hepatol. 2019 Jun;70(6):1093-1102. doi: 10.1016/j.jhep.2019.02.006. Epub 2019 Feb 20.

PMID:
30794889
19.

[Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue®) in the prevention of opioid overdoses].

Lenglard F, Berger-Vergiat A, Ragonnet D, Duvernay N, Lack P, Poulet E, Zoulim F, Chappuy M.

Therapie. 2019 Sep;74(4):477-486. doi: 10.1016/j.therap.2019.01.005. Epub 2019 Jan 24. French.

PMID:
30792078
20.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.

Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group.

Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13.

PMID:
30768988
21.

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort.

Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.

PMID:
30765123
22.

Non-F HBV/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon.

Melo Da Silva E, Kay A, Lobato C, Muwonge R, Zoulim F, Brites C, Parana R, Trepo C.

J Med Virol. 2019 Jun;91(6):1081-1086. doi: 10.1002/jmv.25411. Epub 2019 Feb 11.

PMID:
30695106
23.

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.

Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F.

J Hepatol. 2019 Apr;70(4):615-625. doi: 10.1016/j.jhep.2018.11.030. Epub 2018 Dec 7.

PMID:
30529504
24.

Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection.

Malagnino V, Bottero J, Miailhes P, Lascoux-Combe C, Girard PM, Zoulim F, Lacombe K, Boyd A.

J Med Virol. 2019 Apr;91(4):630-641. doi: 10.1002/jmv.25360. Epub 2018 Dec 3.

PMID:
30431661
25.

Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.

Brichler S, Nahon P, Zoulim F, Layese R, Bourcier V, Audureau E, Sutton A, Letouze E, Cagnot C, Marcellin P, Guyader D, Roulot D, Pol S, de Ledinghen V, Zarski JP, Calès P, Tran A, Peron JM, Mallat A, Riachi G, Grange JD, Blanc JF, Bacq Y, Ouzan D, Bronowicki JP, Mathurin P, Larrey D, Alric L, Attali P, Serfaty L, Pilette C, Bourlière M, Thabut D, Silvain C, Wartelle C, Zucman D, Christidis C, Roudot-Thoraval F, Ganne-Carrie N; ANRS CO12 CirVir study group.

J Viral Hepat. 2019 Mar;26(3):384-396. doi: 10.1111/jvh.13029. Epub 2019 Jan 16.

PMID:
30380181
26.

Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues.

Chevaliez S, Rodriguez C, Poiteau L, Soulier A, Donati F, Darty-Mercier M, Pioche C, Leroy V, Brodard V, Zoulim F, Brouard C, Larsen C, Semaille C, Roudot-Thoraval F, Pawlotsky JM; Hepatology Reference Centers Laboratories Network for Chronic Hepatitis B Surveillance.

J Viral Hepat. 2019 Feb;26(2):278-286. doi: 10.1111/jvh.13025. Epub 2018 Nov 14.

PMID:
30339311
27.

Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.

Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Danel C, Delaugerre C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study.

Liver Int. 2019 Feb;39(2):280-289. doi: 10.1111/liv.13975. Epub 2018 Oct 17.

28.

Hepatitis B.

Zoulim F, Levrero M, Testoni B.

Nat Rev Gastroenterol Hepatol. 2018 Sep 20. doi: 10.1038/s41575-018-0060-3. [Epub ahead of print] No abstract available.

PMID:
30237516
29.

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.

PMID:
30031138
30.

Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle.

Lahlali T, Berke JM, Vergauwen K, Foca A, Vandyck K, Pauwels F, Zoulim F, Durantel D.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00835-18. doi: 10.1128/AAC.00835-18. Print 2018 Oct.

31.

Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines.

Faure-Dupuy S, Vegna S, Aillot L, Dimier L, Esser K, Broxtermann M, Bonnin M, Bendriss-Vermare N, Rivoire M, Passot G, Lesurtel M, Mabrut JY, Ducerf C, Salvetti A, Protzer U, Zoulim F, Durantel D, Lucifora J.

J Innate Immun. 2018;10(4):339-348. doi: 10.1159/000489966. Epub 2018 Jul 5.

32.

Very late relapse of hepatitis C virus infection immediately after liver transplant.

Erard-Poinsot D, Scholtès C, Billoud C, Zoulim F, Dumortier J.

Am J Transplant. 2018 Oct;18(10):2587-2590. doi: 10.1111/ajt.14965. Epub 2018 Jul 2.

33.

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R.

N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519.

34.

Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.

Miailhes P, Hartig-Lavie K, Virlogeux V, Pradat P, Diakite M, Uhres AC, Zoulim F, Sarda MN.

Clin Microbiol Infect. 2018 Nov;24(11):1215.e1-1215.e4. doi: 10.1016/j.cmi.2018.05.019. Epub 2018 Jun 2.

PMID:
29870852
35.

Perspectives and limitations for nucleo(t)side analogs in future HBV therapies.

Levrero M, Subic M, Villeret F, Zoulim F.

Curr Opin Virol. 2018 Jun;30:80-89. doi: 10.1016/j.coviro.2018.04.006. Epub 2018 May 16. Review.

PMID:
29777955
36.

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3.

PMID:
29729258
37.

Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults.

Komas NP, Ghosh S, Abdou-Chekaraou M, Pradat P, Al Hawajri N, Manirakiza A, Laghoe GL, Bekondi C, Brichler S, Ouavéné JO, Sépou A, Yambiyo BM, Gody JC, Fikouma V, Gerber A, Abeywickrama Samarakoon N, Alfaiate D, Scholtès C, Martel N, Le Gal F, Lo Pinto H, Amri I, Hantz O, Durantel D, Lesbordes JL, Gordien E, Merle P, Drugan T, Trépo C, Zoulim F, Cortay JC, Kay AC, Dény P.

PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006377. doi: 10.1371/journal.pntd.0006377. eCollection 2018 Apr.

38.

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.

Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, DI Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1245-1259. doi: 10.1002/hep.30034. Epub 2018 Jul 10.

PMID:
29663511
39.

Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.

Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Delaugerre C, Danel C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study.

J Viral Hepat. 2018 Oct;25(10):1121-1131. doi: 10.1111/jvh.12914. Epub 2018 May 9.

PMID:
29660214
40.

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.

Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group.

Am Heart J. 2018 Apr;198:4-17. doi: 10.1016/j.ahj.2017.10.024. Epub 2017 Nov 7.

PMID:
29653647
41.

Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes.

Lucifora J, Bonnin M, Aillot L, Fusil F, Maadadi S, Dimier L, Michelet M, Floriot O, Ollivier A, Rivoire M, Ait-Goughoulte M, Daffis S, Fletcher SP, Salvetti A, Cosset FL, Zoulim F, Durantel D.

Sci Rep. 2018 Mar 29;8(1):5390. doi: 10.1038/s41598-018-23525-w.

42.

Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.

Virlogeux V, Berthillon P, Bordes I, Larrat S, Crouy S, Scholtès C, Pradat P, Maynard M, Zoulim F, Leroy V, Chemin I, Trépo C, Petit MA.

Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):313-318. doi: 10.1016/j.clinre.2018.02.002. Epub 2018 Mar 16.

PMID:
29551607
43.

CD4+ T Cell Recovery and Hepatitis B Virus Coinfection in HIV-Infected Patients from Côte d'Ivoire Initiating Antiretroviral Therapy.

Houghtaling L, Moh R, Abdou Chekaraou M, Gabillard D, Anglaret X, Eholié SP, Zoulim F, Danel C, Lacombe K, Boyd A.

AIDS Res Hum Retroviruses. 2018 May;34(5):439-445. doi: 10.1089/AID.2017.0272. Epub 2018 Mar 20.

PMID:
29466862
44.

Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells.

Aillot L, Bonnin M, Ait-Goughoulte M, Bendriss-Vermare N, Maadadi S, Dimier L, Subic M, Scholtes C, Najera I, Zoulim F, Lucifora J, Durantel D.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01741-17. doi: 10.1128/AAC.01741-17. Print 2018 Apr.

45.

How to improve access to therapy in hepatitis B patients.

Subic M, Zoulim F.

Liver Int. 2018 Feb;38 Suppl 1:115-121. doi: 10.1111/liv.13640. Review.

PMID:
29427482
46.

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.

Zoulim F, Moreno C, Lee SS, Buggisch P, Horban A, Lawitz E, Corbett C, Lenz O, Fevery B, Verbinnen T, Shukla U, Jessner W.

Virol J. 2018 Jan 30;15(1):26. doi: 10.1186/s12985-018-0936-4.

47.

Hepatocellular carcinoma-associated depletion of the netrin-1 receptor Uncoordinated Phenotype-5A (UNC5A) skews the hepatic unfolded protein response towards prosurvival outcomes.

Barnault R, Lahlali T, Plissonnier ML, Romero-López C, Laverdure N, Ducarouge B, Rivoire M, Mehlen P, Zoulim F, Parent R.

Biochem Biophys Res Commun. 2018 Jan 22;495(4):2425-2431. doi: 10.1016/j.bbrc.2017.12.129. Epub 2017 Dec 24.

PMID:
29277614
48.

Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.

Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L; ANRS HC32 QUATTRO study group.

Eur J Gastroenterol Hepatol. 2018 Mar;30(3):302-309. doi: 10.1097/MEG.0000000000001035.

PMID:
29271782
49.

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.

Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat’AIDS Study Group.

BMC Med. 2017 Dec 18;15(1):217. doi: 10.1186/s12916-017-0979-1.

50.

Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.

Niu C, Li L, Daffis S, Lucifora J, Bonnin M, Maadadi S, Salas E, Chu R, Ramos H, Livingston CM, Beran RK, Garg AV, Balsitis S, Durantel D, Zoulim F, Delaney WE 4th, Fletcher SP.

J Hepatol. 2018 May;68(5):922-931. doi: 10.1016/j.jhep.2017.12.007. Epub 2017 Dec 13.

PMID:
29247725

Supplemental Content

Loading ...
Support Center